Sartorius Unveils New Platform to Enhance Cell Therapy Production

Sartorius, a leading entity in life sciences, announced the launch of the Eveo Cell Therapy Platform. This platform aims to boost efficiency in the production of autologous cell therapies by enabling automated, multi-parallel intensified production. A compact design allows a fourfold increase in output within existing cleanroom spaces.

With potential cost reductions of up to 90% in CAR-T processes, Sartorius is tackling manufacturing bottlenecks through this integrated system. The pilot project with CDMO ElevateBio demonstrated the platform's applicability, confirming that a single operator can process eight patient batches simultaneously. This results in producing over 350 doses annually, compared to the current 100 doses.

Quality control is enhanced with live cell imaging and high throughput flow cytometry, overcoming significant analytical challenges. Sartorius plans to begin orders in September 2026, with deliveries expected in 2027.